Biomarkers for Endocrine Therapy Resistance in Metastatic Breast Cancer
This study is looking for better ways to tell if endocrine therapy is working for people with metastatic lobular breast cancer (LBC). You may be able to join if you are starting new endocrine therapy for ER/PR-positive (estrogen receptor/progesterone receptor positive) and HER2-negative advanced or metastatic LBC. Researchers will use a special imaging agent called 18F-fluorofuranylnorprogesterone (FFNP) with PET/CT scans, and also collect blood samples (liquid biopsies). They want to see if changes in these measurements after 4 weeks of treatment can predict how well you respond to endocrine therapy. The study aims to find 'biomarkers' (signs in your body) that show if the treatment is effective.
- Study design
- This is a pilot observational study with 8 participants. It is not specified if it is randomized or blinded.
- What's involved
- You would have FFNP-PET/CT scans and blood draws (liquid biopsies) at the beginning of the study and again after 4 weeks of treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoints are measured at baseline and 4 weeks, but longer-term follow-up is not specified.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Biomarkers to Detect Endocrine Therapy Resistance
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Marina Sharifi, MD, PHD · PRINCIPAL_INVESTIGATOR · UW Carbone Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Number of Participants who have decreased FFNP uptake on PET/CT in response to endocrine therapybaseline, 4 weeks
- Number of Participants who have decrease in circulating tumor cell estrogen signaling in response to endocrine therapybaseline, 4 weeks
Baseline level and on-treatment CTC ESR1 and estrogen regulated gene expression will be evaluated as well as endocrine-resistance associated mutations including ESR1 (though rare in this patient population) and PGR.
- Number of Participants who have a decrease in concentration of Circulating Tumor DNA in response to endocrine therapybaseline, 4 weeks